Antares Pharma (ATRS) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Antares Pharma (NASDAQ:ATRS) in a research note released on Monday morning, AnalystRatings.com reports. They currently have a $4.50 target price on the specialty pharmaceutical company’s stock.

“We’re encouraged to see Teva Rx share jump to 9.7% in the latest data (week ending 4/26; Figure 1), and we model 25% in 3Q19. Thus, we expect strong continuing device orders and growing Antares royalty revenue in 2H19. Makena orders from partner AMAG (AMAG; not rated) were also up QoQ and should be a steady contributor. As we published in March, we do not expect Makena to be pulled from the market following the failed post-approval PROLONG study. Last, but certainly not least important, Xyosted Rx are off to a solid start. Sales in the quarter were de minimis (likely under $1M), but Rx volume was up 66% sequentially in March and the latest data showed new highs, and at our estimated steady-state $340/Rx, sales are running at $11-12M now (Figure 2).”,” the firm’s analyst commented.

Other equities analysts also recently issued research reports about the company. BidaskClub raised Antares Pharma from a hold rating to a buy rating in a research report on Wednesday, March 6th. TheStreet raised Antares Pharma from a d rating to a c rating in a research report on Friday, March 1st. Cowen started coverage on Antares Pharma in a research report on Monday, February 25th. They set an outperform rating and a $1.99 price target on the stock. Finally, Raymond James boosted their price target on Antares Pharma from $5.25 to $5.65 and gave the stock a strong-buy rating in a research report on Monday, March 4th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Antares Pharma currently has a consensus rating of Buy and an average price target of $4.83.

Shares of NASDAQ ATRS opened at $2.96 on Monday. The company has a market cap of $482.17 million, a price-to-earnings ratio of -74.00 and a beta of 1.03. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.20 and a current ratio of 2.62. Antares Pharma has a twelve month low of $2.35 and a twelve month high of $3.96.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. The firm had revenue of $23.29 million for the quarter, compared to the consensus estimate of $17.46 million. Antares Pharma had a negative return on equity of 19.98% and a negative net margin of 7.91%. On average, analysts anticipate that Antares Pharma will post -0.06 earnings per share for the current fiscal year.

In other news, Director Leonard S. Jacob sold 92,078 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $3.00, for a total transaction of $276,234.00. Following the completion of the sale, the director now owns 301,970 shares in the company, valued at $905,910. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $2.67, for a total value of $80,100.00. Following the sale, the director now owns 190,213 shares of the company’s stock, valued at approximately $507,868.71. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 322,078 shares of company stock valued at $1,086,334. Corporate insiders own 12.20% of the company’s stock.

Several large investors have recently modified their holdings of the company. Advisor Group Inc. boosted its holdings in shares of Antares Pharma by 7.8% during the first quarter. Advisor Group Inc. now owns 48,498 shares of the specialty pharmaceutical company’s stock worth $147,000 after acquiring an additional 3,511 shares during the period. Legal & General Group Plc boosted its holdings in shares of Antares Pharma by 16.6% during the fourth quarter. Legal & General Group Plc now owns 25,244 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 3,587 shares during the period. NewSquare Capital LLC boosted its holdings in shares of Antares Pharma by 33.8% during the fourth quarter. NewSquare Capital LLC now owns 21,611 shares of the specialty pharmaceutical company’s stock worth $59,000 after acquiring an additional 5,460 shares during the period. Northern Trust Corp boosted its holdings in shares of Antares Pharma by 0.4% during the fourth quarter. Northern Trust Corp now owns 1,741,602 shares of the specialty pharmaceutical company’s stock worth $4,738,000 after acquiring an additional 6,868 shares during the period. Finally, Alpine Woods Capital Investors LLC bought a new stake in shares of Antares Pharma during the first quarter worth approximately $30,000. Institutional investors own 40.73% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: Understanding Specialty Certificates of Deposit

Analyst Recommendations for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.